Clinical Trial Update: The Effect of FP-025, on Allergen-induced Airway Responses in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma. [Phase 2]

View source ↗

Summary

Phase 2 trial results for FP-025 evaluating its effect on allergen-induced airway responses in mild eosinophilic house dust mite–allergic asthma have been compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• FP-025

Snippet

Sponsor: Foresee Pharmaceuticals Co., Ltd. | Conditions: Asthma, COPD | Phase 2 | Status: COMPLETED | Results posted: 2024-05-30